Natera, Inc. (NASDAQ:NTRA) CFO Sells $233,416.54 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,442 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $161.87, for a total value of $233,416.54. Following the completion of the transaction, the chief financial officer now owns 108,032 shares of the company’s stock, valued at approximately $17,487,139.84. This trade represents a 1.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Price Performance

Natera stock opened at $168.22 on Thursday. The business has a 50-day simple moving average of $166.56 and a two-hundred day simple moving average of $137.43. Natera, Inc. has a 52-week low of $64.74 and a 52-week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.95) EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Chartwell Investment Partners LLC lifted its position in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after buying an additional 11,362 shares in the last quarter. Cerity Partners LLC lifted its holdings in Natera by 27.0% in the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Natera in the 3rd quarter worth approximately $385,000. Everence Capital Management Inc. purchased a new position in Natera in the 4th quarter worth approximately $573,000. Finally, First Turn Management LLC purchased a new position in Natera in the 3rd quarter worth approximately $19,760,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group increased their target price on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday. Guggenheim increased their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Leerink Partners increased their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Finally, Canaccord Genuity Group increased their target price on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.